Lupus

LRA.logo

LRA Awards for Immune Resetting Therapies in Lupus

Lupus Research Alliance

Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of

Read Article
Population cohort study of pregnancies from UK Clinical Practice Research Datalink, 5.2 million pregnancies, ~2.5 mill births. Incr risk for miscarriage in Sjögrens (aRR 1.66), C-sect in IBD (1.27), SGA in SLE (2.45), preterm birth in RA (1.53), stillbirth in SLE (1.82) & more https://t.co/IjtRTE2t78
Dr. John Cush @RheumNow( View Tweet )
30 yr Retrospective study of 1216 SLE hospitalizations in Barcelona - SLE flares & infections were most frequent. Hosp for infections signif. increased & in last 5yrs, exceeded Dz flares (34% vs. 26%). Younger pts had more flare hosp; older more infx hosp. Over time infx have https://t.co/TkUiXaoL1R
Dr. John Cush @RheumNow( View Tweet )
Case-control study of 349 autoimmune (ARD) pts (SLE, RA, SSc) & serum assays for anti-neutrophil extracellular trap (aNET)Abs. aNET in 37% SLE assoc w/ APS (OR 3.4) & arterial thrombosis (OR 5.5). aNET in 40% RA assoc w/ ACPA+ (p=0.049) https://t.co/QwvmLAVmg7 https://t.co/VJ7JV5fcZE

Links:

Dr. John Cush @RheumNow( View Tweet )
lupus.nephritis.immunofluorescence.jpg

Trends and Innovations in Lupus Nephritis Clinical Trials

Jack Cush, MD

Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.

Read Article
Canada’s Drug Agency (CDA-AMC) has recommended Gazyva (obinutuzumab) for public reimbursement. This recommendation is for the treatment of adult patients with active lupus nephritis who are receiving standard therapy https://t.co/TC1MVAShdC https://t.co/flXVmLwGtW

Links:

Dr. John Cush @RheumNow( View Tweet )
Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon (IFN-I), drive systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). A recent comprehensive review synthesizes the https://t.co/VaE295a2Ep
Dr. John Cush @RheumNow( View Tweet )
True or False: In a Japanese study of refractory neuropsychiatric SLE, rituximab led to significant improvement in the majority of patients treated. See if you got it right at https://t.co/3F1h89Qrtw https://t.co/vx0ILsZ3WF

Links:

Dr. John Cush @RheumNow( View Tweet )
Fatigue in SLE An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients. https://t.co/63JVDUwu88 https://t.co/3dPOThMbMD

Links:

Dr. John Cush @RheumNow( View Tweet )
HCQ: 5 mg/kg/day Is Only the Starting Point HCQ is one of the most important drugs in rheumatology, especially for SLE. It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival. Yet many clinicians still prescribe HCQ as if https://t.co/Fwr92tuZf2
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Quiz Talk (5.22.2026)

Jack Cush, MD

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

Read Article
Does RTX work in CNS lupus? Japanese experience in 17 refractory NP-SLE pts Rx w/ RTX - 16/17 had significant improve. & 1 partial improvement -- none had NP-SLE relapse. Two died during COVID> https://t.co/GpCgpSxn37 https://t.co/PMz05MHBhj

Links:

Dr. John Cush @RheumNow( View Tweet )
lupus.skinbx.jpg

A Role for Plasmacytoid Dendritic Cells in Lupus

Jack Cush, MD

Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon, drive systemic lupus erythematosus and cutaneous lupus erythematosus. A recent comprehensive review synthesizes the available data on pDCs, and,

Read Article
True or False: In a registry of SLE patients, RNP-positive patients showed lower disease activity and less prednisone use. If you think you know the answer, prove it in this week's RheumIQ quiz at https://t.co/DTabBEfjj9

Links:

Dr. John Cush @RheumNow( View Tweet )

colitis.jpg

Early GI Involvement Predictive of Scleroderma Outcomes

Jack Cush, MD

Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc).

Read Article
HCQ target dosing using bullseye imagery

Hydroxychloroquine: 5 mg/kg/day Is Only the Starting Point

Shivani Garg, MD, PhD  Donald E Thomas Jr

Hydroxychloroquine (HCQ) is one of the most important drugs in rheumatology, especially for systemic lupus erythematosus (SLE). It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival. Yet many clinicians still prescribe HCQ as

Read Article
Fatigue in SLE An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients. https://t.co/JEAnhMFJD8 https://t.co/sROKzsyISl

Links:

Dr. John Cush @RheumNow( View Tweet )
Registry of 587 #SLE pts. 30% were RNP+ --> more dz activity than RNP- (SLEDAI-2 8.0 vs 4.0) and more Rx use (daily GC 6.8 vs 3 mg). RNP+  more renal, skin & serologic activity & less likely to LLDAS (20% vs 32%) or REM (12% vs 23%). RNP + 18-fold more likely to be Sm+ https://t.co/9i3BBGA0uu
Dr. John Cush @RheumNow( View Tweet )
Meet the RheumNow #EULAR2026 Reporting Team Delivering real-time insights from the forefront of rheumatology: 🩺 Dr. Antoni Chan (@synovialjoints) 🩺 Dr. Mrinalini Dey (@DrMiniDey) 🩺 Dr. Jiha Lee (@JihaRheum) 🩺 Dr. Aurelie Najm (@AurelieRheumo) 🩺 Dr. Janet Pope https://t.co/zpIeGWpL6P
Dr. John Cush @RheumNow( View Tweet )
Toll-Like Receptor Drugs Effective in Cutaneous Lupus Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial. https://t.co/R1wbJHXwjD https://t.co/65HtG0Te94

Links:

Dr. John Cush @RheumNow( View Tweet )
Lupus Mortality Risk in Young Women New research using death certificate data from 52,942 females, reveals that systemic lupus erythematosus (lupus) is a leading cause of years of potential life lost among young women in the United States, underscoring the disease’s significant https://t.co/2FSINr6gZN
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Infectious Rheumatology (5.15.2026)

Jack Cush, MD

Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.

Read Article
Sleep.fatigue.doctor.jpg

Fatigue in SLE

Jack Cush, MD

An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients.

Read Article
Registry of 587 #SLE pts. 30% were RNP+ --> more dz activity than RNP- (SLEDAI-2 8.0 vs 4.0) and more Rx use (daily GC 6.8 vs 3 mg). RNP+  more renal, skin & serologic activity & less likely to LLDAS (20% vs 32%) or REM (12% vs 23%). RNP + 18-fold more likely to be Sm+ https://t.co/3J0Uew48OS
Dr. John Cush @RheumNow( View Tweet )
lupus.skinbx.jpg

Toll-Like Receptor Drugs Effective in Cutaneous Lupus

MedPage Today

Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.

Read Article

Therapeutic Updates

Expert insights on the 2024 ACR Guideline recommendations for lupus nephritis

Sponsored by Aurinia
Aurinia 2026 May RX Update
Two experts in lupus care offer a balanced perspective on applying the updated ACR Guideline recommendations and the clinical nuances of managing lupus nephritis.
Read Post

Recent Blogs

Advanced Practice Rheum

Systemic Lupus Erythematosus

Jack Cush, MD
APR SLE VIDEO COVER
Dr. Cush reviews systemic lupus erythematosus.
Read Article
Advanced Practice Rheum

Evaluation of Rheumatic Complaints

Jack Cush, MD
Eval of Rheum Complaints Cover Image
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article
rheumthought

CNS Lupus (NPSLE)

Jack Cush, MD
Cush RhTh CNS
29 yr. old woman with SLE and transverse myelitis. Is this NPSLE; how to diagnose?
Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • ACR 2025 Daily Podcasts Day4a
  • ACR 2025 Daily Podcasts Day3b
  • ACR 2025 Daily Podcasts Day2b
×